Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
Lucila Rey-AresAhuva AverinMercedes Mac MullenDhwani HariharanMark AtwoodCarolina CarballoLiping HuangPublished in: Infectious diseases and therapy (2024)
Analyses suggest implementing a PCV20 vaccination program in moderate-/high-risk adults aged 18-64 years and all adults ≥ 65 years-in lieu of PCV13 → PPSV23-would yield substantial reductions in pneumococcal disease and would be cost saving to the Argentinean healthcare system.